Analysts have maintained their price target for Eisai at ¥5,026.92, citing only minor adjustments to revenue growth and profit margin estimates. These adjustments did not significantly influence their overall valuation.
What's in the News
- Eisai and its partner BioArctic will present new long-term data and real-world clinical practice findings on lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease (CTAD) conference. Topics include studies on subcutaneous initiation dosing, safety, and patient experiences. (Key Developments)
- Leqembi (lecanemab) received approval for once every four weeks intravenous maintenance dosing for early Alzheimer's disease in the United Kingdom. This expands treatment options for patients and marks additional regulatory milestones. (Key Developments)
- Eisai reached settlements with multiple generic drug manufacturers, including Torrent Pharmaceuticals and Dr. Reddy’s Laboratories, regarding patent litigation over Lenvima (lenvatinib). Generic entry in the U.S. is agreed not before July 1, 2030, barring certain conditions. (Key Developments)
- Merck and Eisai announced positive clinical trial results for the combination of KEYTRUDA (pembrolizumab) and LENVIMA (lenvatinib), supporting use in advanced cancers such as hepatocellular carcinoma and renal cell carcinoma. (Key Developments)
- Eisai received a Fast Track designation from the U.S. FDA for etalanetug, an investigational antibody targeting tau in Alzheimer's disease, aiming to accelerate development for this unmet medical need. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target remains unchanged at ¥5,026.92.
- Discount Rate holds steady at 4.8%.
- Revenue Growth estimate has fallen slightly, decreasing from 3.95% to 3.87%.
- Net Profit Margin has declined marginally from 7.53% to 7.49%.
- Future P/E has increased slightly from 23.91x to 24.09x.
Have other thoughts on Eisai?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.